上海瑞凝生物科技有限公司 成立日期： 2018年 总部所在地： 上海 企业定位： 医用水凝胶技术平台企业 主要业务领域： 肿瘤治疗等重大临床场景的创新医疗器械 # 产品与技术简介 公司主要产品包括： 近日， 上海瑞凝生物科技有限公司 完成近亿元人民币C轮融资 。本轮融资由复旦科创与启明 创投联合领投，浩悦资本担任独家财务顾问。资金将用于核心产品的临床推进与商业化。 # 公司介绍 | | 注册证编号 | 注册人名称 | 产品名称 | | --- | --- | --- | --- | | | 国械注准20263050277 | 上海瑞凝生物科技有限公司 | 可吸收隔离水凝胶 | # 融资历程 据思宇MedTech查询企查查网站，该公司融资历程如下表： Respacio®肿瘤放疗"可吸收隔离水凝胶" 用于肿瘤放疗防护，已完成国内临床。入选国家药监局创新医疗器械特别审查程序，获美国 FDA突破性医疗器械认定，已递交欧洲CE认证申请。 肿瘤栓塞水凝胶 用于富血管恶性肿瘤治疗的原位固化PEG栓塞水凝胶，入选国家药监局创新医疗器械特别审查程序。 宫腔防粘连水凝胶 用于术后预防宫腔粘连的PEG水凝胶产品，目前处于临床入组阶 ...

根据公告，该产品用于体外定性检测非小细胞肺癌（NSCLC）及结直肠癌（CRC）患者福尔马林固定石蜡包埋（FFPE）组织样本中的EGFR、KRAS、PIK3CA、 BRAF和ERBB2基因变异。 这是 国内首款基于 飞行时间质谱法 获批上市的肿瘤伴随诊断试剂盒 。 2026年3月1日， 中源协和细胞基因工程股份有限公司 发布公告称，其控股子公司 中源维康（天津）医学检验所有限公司 获得国家药品监督管理局颁发的III类《医 疗器械注册证》。产品为 人EGFR/KRAS/BRAF/ERBB2/PIK3CA基因突变检测试剂盒（飞行时间质谱法） ，注册证编号为国械注准20263400419，有效期5年。 中源维康为中源协和控股96.77%的子公司，主要从事精准医学检验与分子诊断相关业务。 一、医疗器械注册证基本情况 | 注册人名称 | 中源维康(天津)医学检验所有限公司 | | --- | --- | | 产品名称 | 人 EGFR/KRAS/BRAF/ERBB2/PIK3CA 基因突变检测试剂盒 | | | (飞行时间质谱法) | | 注册分类 | III 类 | | 注册证编号 | 国械注准 20263400419 ...

事项： ❖ 公司近日发布 2025 年盈喜预告，营收不低于 6.5 亿元，同比增长约 88.1%，并 实现不低于 0.38 亿元的净利润(24 年同期亏损 0.63 亿元)，扭亏为盈。 评论： [主要财务指标 Indicator_FinchinaSimpleHK] 港股公司 证 券 研 究 报 告 微泰医疗-B（02235.Hk）2025 年业绩预告点评 强推（维持） 营收增长超预期，利润端实现扭亏 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万元) | 346 | 651 | 882 | 1,161 | | 同比增速(%) | 36.5% | 88.3% | 35.6% | 31.6% | | 归母净利润(百万元) | -63 | 38 | 93 | 152 | | 同比增速(%) | 49.5% | 160.7% | 143.2% | 63.5% | | 每股盈利(元) | -0.15 | 0.09 | 0.22 | 0.36 | | 市盈率(倍) | -45 | 74 | 30 | 19 | | ...

策略研究报告 证券研究报告 策略报告 报告日期：2026 年 3 月 1 日 风险因素影响可控 ——A 股投资策略周报告 华龙证券研究所 A 股市场走势(2025/2/14-2026/2/27) 姓 名：朱金金 执业证书编号：S0230521030009 邮 箱：zhujj@hlzq.com | 表 1:风格涨跌幅 | | --- | | 表 2: 美伊谈判及冲突事件 . | | 表 3: 主要宽基指数市盈率(TM)及市净率(LF)估值分位 7 | | 表 4: 行业市盈率(TTM)及市净率(LF)估值分位 . | 影响有限》2026.2.2 2026.2.2 稳中向好》2026.1.19 请认真阅读文后免责条款 摘要（核心观点）： 上周周期风格涨幅居前。周期板块上周整体表现较好，主要原因包括：一 是春节期间美伊局势复杂，市场对冲突担忧升温，推动国际油价上升，以 及美国关税政策的不确定性加剧市场对美元信用担忧，推升贵金属避险需 求。二是供给约束与基本面改善等因素影响，钢铁、有色金属、基础化工 等周期行业板块涨幅居前。三是风格轮动与资金偏好影响。周期板块估值 相对较低且有基本面支撑，吸引了局部高估板块的资金向周 ...

Summary of Carlsmed Conference Call Company Overview - **Company**: Carlsmed - **Industry**: Medical Device, specifically focused on spine surgery - **Founded**: 2018 - **Public Company Status**: Recently went public Core Business and Technology - Carlsmed aims to improve healthcare outcomes and reduce costs in spine surgery by minimizing patient reoperations through a comprehensive technology platform that spans preoperative, intraoperative, and postoperative phases [2][3] - The company has developed the **aprevo® Technology Platform**, which allows for virtual modeling of patient pathology and creation of personalized surgical plans and devices [6][10] Financial Performance - **Q4 Revenue**: Over $15 million with a gross margin of 76.5%, representing a year-on-year growth of 61% [3] - **Full Year Revenue**: $50.5 million in the first year as a public company, an 86% year-on-year growth [3] - **2023 Revenue Guidance**: Projected revenue between $70 million and $75.5 million, indicating a growth of 44% at the midpoint [4] Market Opportunity - The U.S. spine surgery market includes approximately 445,000 lumbar procedures and 373,000 cervical procedures annually, totaling over 800,000 addressable procedures [5][6] - Carlsmed has seen a nearly 70% increase in its user base, ending the year with 253 trained surgeon users [4] Clinical Validation and Outcomes - Clinical data published in the Global Spine Journal indicates a 74% reduction in revision rates at the two-year mark for patients undergoing the aprevo personalized surgery compared to traditional methods [7] - The company has received Breakthrough Device Designation from the FDA, which facilitates better reimbursement options for its technologies [13][18] Reimbursement and Adoption - Carlsmed has secured a New Technology Add-on Payment from Medicare, providing over $21,000 in incremental reimbursement for hospitals adopting its cervical technology [18] - The company emphasizes the importance of payer support for technology adoption, which can lead to improved patient outcomes and reduced costs [11][14] Product Innovations - The company has expanded its platform to include cervical surgery, addressing specific challenges such as subsidence in patients with osteoporosis [15][18] - Recent innovations include a personalized cervical plating platform and a bilateral approach for minimally invasive procedures, enhancing the surgical experience and outcomes [20][21] Future Outlook - Carlsmed is focused on expanding its technology within the spine market before considering applications in other medical segments [28] - The company aims to continue its rapid growth trajectory and enhance the adoption of its personalized surgery approach [22] Additional Insights - The company utilizes a hybrid commercial model, leveraging both sales agents and direct teams for customer acquisition and support [4] - The technology allows for a zero-inventory business model, simplifying logistics for hospitals [21] - Carlsmed is aware of ongoing clinical studies involving wearable technology for post-operative recovery, although it is not directly integrating such technology at this time [22]

Summary of Establishment Labs FY Conference Call Company Overview - **Company**: Establishment Labs (NasdaqCM: ESTA) - **Industry**: Medical Devices, specifically breast implants Key Points 2025 Performance and 2026 Outlook - Establishment Labs had an outstanding performance in 2025, exceeding initial expectations with the successful launch of the Motiva implant, opening 1,500 accounts, which was beyond the original plan [9][10] - The company expects strong momentum to continue into 2026, with guidance indicating at least 30% revenue growth, aiming for a midpoint revenue of $265 million [30][31] Drivers of Success - The success in 2025 was attributed to innovative marketing strategies, including partnerships with influencers and celebrities like Meghan Trainor, which significantly increased demand [13][15] - The company has been adding new accounts consistently, with a commercial team that reportedly hasn't gone a day without adding a new account [8][10] - The Preservé launch outside the U.S. has also been successful and is expected to drive growth in 2026 [11] Pricing Strategy - The pricing strategy for Motiva has been effective, with no significant pushback from the market. The company has maintained premium pricing due to the perceived value of their products [17][18] - Surgeons are reportedly charging a premium for procedures using Motiva, with increases of 30%-50% for those surgeries [46][50] Market Dynamics - The U.S. market has shown a stable demand for Ergonomix implants, with approximately 55%-60% of sales coming from this premium product line [21] - The company anticipates that the introduction of smaller size Motiva implants will capture an additional 10% of the market [65] International Business - Establishment Labs is focusing on direct markets, which offer better economics, and has seen healthy growth in international markets [71][72] - The company is optimistic about the Chinese market, expecting to achieve a dominant share similar to other Asian markets [73] Future Innovations and Expansion - The company is preparing for the reconstruction market, which could double their total addressable market (TAM). They are awaiting FDA approval for their reconstruction products [58][60] - Establishment Labs aims to democratize breast reconstruction and improve aesthetic outcomes, which could drive further adoption [63] Margin Expansion - The company expects gross margin expansion as they shift focus to higher-margin products and reduce dependency on distribution markets [67] Strategic Leadership Changes - The transition of CFO Raj Denhoy to a strategic role within the company is seen as a move to enhance business development and innovation initiatives [32][38] Additional Insights - The company has a conservative guidance approach, learning from market dynamics as they grow in the U.S. [31] - There is potential upside in revenue projections, particularly with the Preservé product line and the minimally invasive portfolio [74][76] This summary encapsulates the key insights from the Establishment Labs FY Conference Call, highlighting the company's strong performance, strategic initiatives, and future growth potential in the breast implant market.

2025 年 AI 医疗器械品牌推荐 重构医疗生态的 AI 驱动型领跑者 | 一、市场背景 | 2 | | --- | --- | | 1.1 摘要 | 2 | | 1.2AI 医疗器械定义 | 2 | | 1.3 市场演变 | 2 | | 二、市场现状 | 3 | | 2.1 市场规模 | 3 | | 2.2 市场供需 | 3 | | 三、市场竞争 | 4 | | 3.1 市场评估维度 | 4 | | 3.2 市场竞争格局 | 4 | | 3.3 十大品牌推荐 | 5 | | 四、发展趋势 | 6 | | 4.1 技术融合与创新深化：多模态与生成式 AI 驱动诊疗升级 | 6 | | 4.2 政策与监管体系完善：全生命周期管理加速产品合规化 | 7 | | 4.3 市场扩容与场景拓展：基层医疗与消费级市场成新增长极 | 7 | | 4.4 生态协同与国际化突破：产学研用融合推动全链条创新 | 7 | 2025 年 AI 医疗器械品牌推荐 一、市场背景 1.1 摘要 AI 医疗器械行业基于医疗器械数据，采用人工智能技术实现医疗用途。国家药监局颁 布相关指导原则，规范行业生存周期过程。行业应用领域广泛，入局企业 ...

2026年2月27日，国家药品监督管理局创新医疗器械审查办公室发布公示，阿里巴巴达摩院（北京）科技有限公司申报的"胰腺病变CT图像辅助分诊软件"拟进入创 新医疗器械特别审查程序。一家互联网科技巨头的医疗AI产品，正式叩开了中国药监体系为"真正创新"预留的快速通道之门。 就在不到一年前的2025年4月，这同一款产品的海外版本已获得美国FDA"突破性医疗器械"认定。国内外"双轨并进"，折射出的是一套完整的、经过深思熟虑的全球 化医疗AI战略。 截止2026年3月2日，达摩院只有一款二类器械获批，因此，思宇MedTech剖析达摩院医疗AI策略， 对于正在寻找第二增长曲线、思考AI转型路径的中国医疗器械公 司而言，达摩院的这盘棋值得仔细拆解。 | 注册证编号 | 京械注准20242210695 | | --- | --- | | 注册人名称 | 阿里巴巴达摩院（北京）科技有限公司 | | 注册人住所 | 北京市朝阳区望京东园四区9号楼28层2801室 | | 生产地址 | 北京市朝阳区广善路21号院-阿里巴巴北京朝阳科技园A区A1楼407室 | | 产品名称 | 医学图像处理软件 | | 管理类别 | 第二类 | | ...

一个更值得注意的细节是： 收入增长42%，利润却实现翻倍，扣非利润增速更是达到141.34%。 这不是 简单的增长，而是盈利能力的显著跃迁。 问题在于：利润为什么可以跑得比收入更快？ 2026年2月27日， 山外山 [688410] 发布2025年业绩快报： 公司实现营业收入80,682.15万元，同比增长42.23%；归母净利润14,311.55万元，同比增长101.89%； 扣非净利润13,799.11万元，同比增长141.34%。 答案其实藏在一条非常典型、但并不常见的路径里：结构变化 + 规模效应。 先看数据拆解： 指标 2024年 2025年 增速 指标 2024年 2025年 增速 营业收入 56,727.45万元 80,682.15万元 +42.23% 归母净利润 7,088.63万元 14,311.55万元 +101.89% 扣非净利润 5,717.79万元 13,799.11万元 +141.34% 数据来源：公司2025年业绩快报 可以看到两个关键变化： 1. 扣非净利润增速显著高于净利润 2. 净利润增速显著高于收入 这意味着利润增长并不是依赖一次性收益，而是来自主营业务本身。 进一步看公 ...

Financial Data and Key Metrics Changes - The company reported a strong finish to 2025, achieving underlying revenue growth of 5.3% and free cash flow of $840 million, a 52.5% increase year-on-year [1][3] - Trading profit for the full year was $1.2 billion, reflecting a 160 basis points margin expansion to 19.7% [17][20] - Adjusted earnings per share grew by 21% to $1.02, driven by a $500 million share buyback [18][19] Business Line Data and Key Metrics Changes - Orthopedics grew by 5.1%, Sports Medicine and ENT by 5.2%, and Advanced Wound Management by 5.6%, all on an underlying basis [15][16] - The joint repair business surpassed $1 billion in revenue for the first time, driven by products like REGENETEN and Q-FIX [11][12] - Advanced Wound Management grew 2.8% in Q4, with Advanced Wound Care growing 4.4% [13][14] Market Data and Key Metrics Changes - U.S. growth was 5.6%, other established markets 7.2%, and emerging markets 6.4%, with underlying growth excluding China at 7.2% [7][16] - The company expects continued growth in orthopedics, sports medicine, and Advanced Wound Management, particularly in AWC and AWD [27][28] Company Strategy and Development Direction - The company is transitioning to a new RISE strategy aimed at accelerating growth and improving returns, building on the previous 12-Point Plan [4][31] - The acquisition of Integrity Orthopaedics is expected to enhance the sports medicine portfolio and drive growth in biomechanical repair [33][34] - The company plans to increase R&D investment and maintain a robust product launch pipeline, with expectations of launching 16 new products in 2026 [43][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving around 6% organic revenue growth in 2026, with trading profit growth expected to be around 8% [20][29] - The impact of China VBP on joint repair is expected to be less significant moving forward, with management anticipating a bounce in sports business in China [72][75] - The company aims to maintain a focus on organic growth and capital allocation towards high-value clinical segments [68][69] Other Important Information - The company achieved a 15-fold increase in free cash flow and a 170 basis points increase in ROIC from 6.6% to 8.3% [6][25] - The company expects to face extraordinary headwinds in 2026, including inventory revaluation and changes to reimbursement in the U.S. AWM business [20][21] Q&A Session Summary Question: Can you break down revenue guidance for 2026 and expectations for market growth? - Management indicated that 2026 revenue growth is expected to be around 6%, with contributions from all business units and innovation driving growth [48][49] Question: What is the expected phasing of revenue growth through the quarters? - Management expects Q1 to be softer due to one fewer trading day, with growth in the first half around 4.5%-5% and stronger growth in Q3 and Q4 [53][54] Question: What is the outlook for joint repair in China? - Management confirmed that joint repair growth in China has annualized, and they expect a bounce in sports business while AET and ENT will have a limited negative impact [64][75]